These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 34073805)

  • 81. Characterization of Antibody-Drug Conjugate Pharmacokinetics and in Vivo Biotransformation Using Quantitative Intact LC-HRMS and Surrogate Analyte LC-MRM.
    Huang Y; Mou S; Wang Y; Mu R; Liang M; Rosenbaum AI
    Anal Chem; 2021 Apr; 93(15):6135-6144. PubMed ID: 33835773
    [TBL] [Abstract][Full Text] [Related]  

  • 82. An overview of site-specific methods for achieving antibody drug conjugates with homogenous drug to antibody ratio.
    Hingorani DV
    Expert Opin Biol Ther; 2024; 24(1-2):31-36. PubMed ID: 38247196
    [TBL] [Abstract][Full Text] [Related]  

  • 83. [Bioanalysis in the development of antibody-drug conjugates].
    Li XL; Chen XY; Zhong DF
    Yao Xue Xue Bao; 2016 Apr; 51(4):517-28. PubMed ID: 29859519
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Development of Solid-Phase Site-Specific Conjugation and Its Application toward Generation of Dual Labeled Antibody and Fab Drug Conjugates.
    Puthenveetil S; Musto S; Loganzo F; Tumey LN; O'Donnell CJ; Graziani E
    Bioconjug Chem; 2016 Apr; 27(4):1030-9. PubMed ID: 26942771
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Efficient Preparation of Site-Specific Antibody-Drug Conjugates Using Cysteine Insertion.
    Dimasi N; Fleming R; Zhong H; Bezabeh B; Kinneer K; Christie RJ; Fazenbaker C; Wu H; Gao C
    Mol Pharm; 2017 May; 14(5):1501-1516. PubMed ID: 28245132
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Site-Specific Conjugation of Monomethyl Auristatin E to Anti-CD30 Antibodies Improves Their Pharmacokinetics and Therapeutic Index in Rodent Models.
    Lhospice F; Brégeon D; Belmant C; Dennler P; Chiotellis A; Fischer E; Gauthier L; Boëdec A; Rispaud H; Savard-Chambard S; Represa A; Schneider N; Paturel C; Sapet M; Delcambre C; Ingoure S; Viaud N; Bonnafous C; Schibli R; Romagné F
    Mol Pharm; 2015 Jun; 12(6):1863-71. PubMed ID: 25625323
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Current ADC Linker Chemistry.
    Jain N; Smith SW; Ghone S; Tomczuk B
    Pharm Res; 2015 Nov; 32(11):3526-40. PubMed ID: 25759187
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Development of an Automated, High-Throughput Methodology for Native Mass Spectrometry and Collision-Induced Unfolding.
    Juliano BR; Keating JW; Li HW; Anders AG; Xie Z; Ruotolo BT
    Anal Chem; 2023 Nov; 95(45):16717-16724. PubMed ID: 37924308
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Drug-to-antibody determination for an antibody-drug-conjugate utilizing cathepsin B digestion coupled with reversed-phase high-pressure liquid chromatography analysis.
    Adamo M; Sun G; Qiu D; Valente J; Lan W; Song H; Bolgar M; Katiyar A; Krishnamurthy G
    J Chromatogr A; 2017 Jan; 1481():44-52. PubMed ID: 28017567
    [TBL] [Abstract][Full Text] [Related]  

  • 90. The impact of trisulfide modification of antibodies on the properties of antibody-drug conjugates manufactured using thiol chemistry.
    Liu R; Chen X; Dushime J; Bogalhas M; Lazar AC; Ryll T; Wang L
    MAbs; 2017 Apr; 9(3):490-497. PubMed ID: 28136017
    [TBL] [Abstract][Full Text] [Related]  

  • 91. AJICAP Second Generation: Improved Chemical Site-Specific Conjugation Technology for Antibody-Drug Conjugate Production.
    Fujii T; Matsuda Y; Seki T; Shikida N; Iwai Y; Ooba Y; Takahashi K; Isokawa M; Kawaguchi S; Hatada N; Watanabe T; Takasugi R; Nakayama A; Shimbo K; Mendelsohn BA; Okuzumi T; Yamada K
    Bioconjug Chem; 2023 Mar; 34(4):728-38. PubMed ID: 36894324
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Site Selection: a Case Study in the Identification of Optimal Cysteine Engineered Antibody Drug Conjugates.
    Tumey LN; Li F; Rago B; Han X; Loganzo F; Musto S; Graziani EI; Puthenveetil S; Casavant J; Marquette K; Clark T; Bikker J; Bennett EM; Barletta F; Piche-Nicholas N; Tam A; O'Donnell CJ; Gerber HP; Tchistiakova L
    AAPS J; 2017 Jul; 19(4):1123-1135. PubMed ID: 28439809
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Highly Potent, Anthracycline-based Antibody-Drug Conjugates Generated by Enzymatic, Site-specific Conjugation.
    Stefan N; Gébleux R; Waldmeier L; Hell T; Escher M; Wolter FI; Grawunder U; Beerli RR
    Mol Cancer Ther; 2017 May; 16(5):879-892. PubMed ID: 28258164
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Conjugation site characterization of antibody-drug conjugates using electron-transfer/higher-energy collision dissociation (EThcD).
    Song Y; Gao J; Meng Q; Tang F; Wang Y; Zeng Y; Huang W; Shao H; Zhou H
    Anal Chim Acta; 2023 Apr; 1251():340978. PubMed ID: 36925279
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody-Drug Conjugate SYD985.
    Elgersma RC; Coumans RG; Huijbregts T; Menge WM; Joosten JA; Spijker HJ; de Groot FM; van der Lee MM; Ubink R; van den Dobbelsteen DJ; Egging DF; Dokter WH; Verheijden GF; Lemmens JM; Timmers CM; Beusker PH
    Mol Pharm; 2015 Jun; 12(6):1813-35. PubMed ID: 25635711
    [TBL] [Abstract][Full Text] [Related]  

  • 96. The Properties of Cysteine-Conjugated Antibody-Drug Conjugates Are Impacted by the IgG Subclass.
    Datta-Mannan A; Choi H; Stokell D; Tang J; Murphy A; Wrobleski A; Feng Y
    AAPS J; 2018 Sep; 20(6):103. PubMed ID: 30255287
    [TBL] [Abstract][Full Text] [Related]  

  • 97. ADME Considerations and Bioanalytical Strategies for Pharmacokinetic Assessments of Antibody-Drug Conjugates.
    Mou S; Huang Y; Rosenbaum AI
    Antibodies (Basel); 2018 Nov; 7(4):. PubMed ID: 31544891
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Influence of disulfide bond isoforms on drug conjugation sites in cysteine-linked IgG2 antibody-drug conjugates.
    Liu-Shin L; Fung A; Malhotra A; Ratnaswamy G
    MAbs; 2018; 10(4):583-595. PubMed ID: 29436897
    [TBL] [Abstract][Full Text] [Related]  

  • 99. [Novel Chemical Linkers for Next-generation Antibody-drug Conjugates(ADCs)].
    Tsuchikama K
    Yakugaku Zasshi; 2019; 139(2):209-219. PubMed ID: 30713230
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Approaches to Interchain Cysteine-Linked ADC Characterization by Mass Spectrometry.
    Valliere-Douglass JF; Hengel SM; Pan LY
    Mol Pharm; 2015 Jun; 12(6):1774-83. PubMed ID: 25474122
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.